Maurizio Simmaco

2 papers in the library · 18 citations · publishing 2025

Papers

Sort Most recent Most cited

The Potential Influence of Associated Antidepressants on the Pharmacokinetic Profile of Esketamine in Patients Affected by Treatment-resistant Depression.

Current Neuropharmacology April 7, 2025 Marika Alborghetti, Luana Lionetto, Ginevra Lombardozzi et al. 1 citation

Esketamine is administered intranasally in combination with at least another antidepressant in patients with treatment-resistant depression. Some of these antidepressants might affect ketamine's pharmacokinetic profile by inhibiting cytochrome-P450 (CYP450) isoforms. Our aim was to establish how different types of combined antidepressants affect serum and salivary levels of esketamine at the...

DOI: 10.2174/011570159X356952241216172603 Full text Depression Antidepressant drugs Cytochrome p450 isoenzymes. Treatment-resistant +3

Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression.

JAMA Psychiatry April 2, 2025 Antonio Del Casale, Sara Spirito, Jan Francesco Arena et al. 17 citations

Treatment-resistant depression (TRD) remains a critical challenge in psychiatry, with limited effective options. Esketamine, a rapid-acting antidepressant, is usually combined with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI), but comparative evidence of these combinations' effectiveness in real-world settings is sparse. To determine...

DOI: 10.1001/jamapsychiatry.2025.0200 Full text Depression treatment Esketamine therapy Antidepressants Mental health research +1